Live Virtual CME Experience
Friday, October 9, 2020 (8:45 am-4:15 pm)
This live virtual conference is intended to provide an update on current evaluation and multi-modality therapy for neurofibromatosis.
Neurofibromatosis represents a group of inheritable disorders that require multi-disciplinary integrated care. Major advances in defining molecular alterations and developing targeted therapies have changed the landscape of treatment, but require continued laboratory and clinical investigations. Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) are pursuing numerous areas of investigation in the clinic and laboratory and we anticipate will become one of the driving forces in the development of newer therapies for both benign and malignant tumors (eg MPNST) in NF-associated tumors. Additionally, MSK is one of the most active surgical groups in the world with the recent integration of advanced technologies such as DaVinci robot resection of paraspinal benign tumors.